Table 1.
Baseline characteristics and LV parameters of the enrolled patients
| Variables | All(n = 84) | Non-responders (n = 34) | Responders (n = 50) | P value |
|---|---|---|---|---|
| Age(year) | 59.3±11.7 | 58.3±10.5 | 60.0±12.5 | 0.800 |
| Male (n, %) | 63 (75.0%) | 26 (76.5%) | 37 (74.0%) | 0.735 |
| Hypertension | 16 (30.8%) | 14 (41.1%) | 16 (32.0%) | 0.005 |
| Diabetes | 10 (19.2%) | 7 (21.0%) | 8 (23.5%) | 0.284 |
| QRS duration (ms) | 154.8±24.0 | 145.3±25.7 | 161.3±20.6 | 0.002 |
| NT-proBNP | 4587.7±3477.6 | 3034.7±3971.4 | 1794.4±1877.9 | 0.068 |
| NS-VT | 52 (61.9%) | 27 (79.4%) | 25 (25.0%) | 0.007 |
| PVC | 1839.4±3472.1 | 2864.5±4667.7 | 1139.6±2124.4 | 0.024 |
| NYHA classII/III/IV | 32/44/8 | 8/21/3 | 24/23/5 | 0.064 |
| Medication | ||||
| ACE inhibitors/ARBs | 68 (81.0%) | 24 (70.6%) | 44 (88.0%) | 0.204 |
| β-Blockers | 82 (97.6%) | 34 (100%) | 48 (96.0%) | 0.148 |
| Diuretics | 80 (95.2%) | 33 (97.1%) | 47 (94.0%) | 0.148 |
| Aldosterone | 80 (95.2%) | 33 (97.1%) | 47 (94.0%) | 0.148 |
| Digoxin | 24 (28.6%) | 14 (41.2%) | 10 (20.0%) | 0.036 |
| LV parameters | ||||
| EDV | 308.4±141.7 | 288.9±130.3 | 321.1±148.8 | 0.309 |
| ESV | 256.6±129.0 | 240.4±113.9 | 267.7±138.4 | 0.346 |
| LVEF (%) | 19.7±9.3 | 21.5±10.0 | 18.6±8.7 | 0.157 |
| Scar burden | 26.6±12.1 | 30.0±11.7 | 24.2±11.9 | 0.031 |
| LV lead in the scarred myocardium | 20 | 13 | 7 | 0.011 |
| Systolic PSD (o) | 43.9±21.9 | 51.3±22.2 | 38.9±20.4 | 0.010 |
| Systolic PBW (o) | 156.2±87.5 | 188.1±88.6 | 134.4±80.5 | 0.005 |
| Diastolic PSD (o) | 54.2±23.4 | 63.0±22.4 | 48.2±22.4 | 0.001 |
| Diastolic PBW (o) | 183.2±90.3 | 220.6±88.5 | 157.8±83.1 | 0.001 |
Data are expressed as mean ± SD or number (percentage)
NT-proBNP, N-terminal pro-natriuretic brain natriuretic peptide; NS-VT, non-sustained ventricular tachycardia; PVC, premature ventricular contraction; CLBBB, complete left bundle branch block; NYHA, New York Heart Association; ACE, angiotensin-converting enzyme; ARBs, angiotensin II receptor blocker; EDV, end-diastolic volume; ESV, end-systolic volume; LVEF, left ventricular ejection fraction